Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020


ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020 at 8:30 am EDT to report financial results for the second quarter ended June 30, 2020 and provide business updates.

To access the call, please dial 646-787-0157 (domestic) or +41-22-5017540 (international) and insert pin number 773478. A live webcast of the presentation will be available under "Events and Presentations" on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available after the completion of the event and for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.

Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company's lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% interim overall response rate (ORR), which exceeded the target primary endpoint. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company's second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical trial. The Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.


These press releases may also interest you

at 10:00
The Canon EOS 6D is the most commonly used camera in 252 images which have made the shortlist for the RMG Astronomy Photographer of the Year competition in 2019 and 2020, according to analysis done by website Skies & Scopes. The camera was originally...

at 06:08
GWM (601633.SS/02333.HK), a leading automobile company in China, has formally announced to transform into a global mobility technology company. GWM has initiated a raft of major strategy upgrade including corporate culture, products, technology and...

at 03:00
PayBito has successfully added thousands of new Indian users in the last three months creating a milestone. Throughout the last few months, the company has been witnessing a significant increase in traffic, constant surges in trading volume, and new...

at 02:00
Qi Card today announced that it has seen increases in two important metrics for the company: in-app usage among current card holders and issuance of new Master Qi Cards. By the close of 2020, Qi Card will have five times more Master Cards in...

at 02:00
GetLinked® reviewed the features most commonly praised by customers in a recent survey. In doing the survey we found that what drives our customer retention is directly related to our mission to save our clients time, money and headaches. Saving time...

25 sep 2020
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Vaxart, Inc. . In early 2020, the Company, which focuses on...



News published on 12 august 2020 at 16:20 and distributed by: